Close Menu

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, OpGen reported after the close of the market on Thursday that its preliminary fourth quarter revenues fell 24 percent from Q4 2015, even as full-year 2016 revenues rose 27 percent.

For the three months ended Dec. 31, 2016, OpGen expects revenues of $1.0 million, down from the $1.3 million the company reported a year ago. Full the full year, OpGen expects revenues of $4.0 million, up from $3.2 million in 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.